A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer.

Trial Profile

A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs Imetelstat (Primary) ; Bevacizumab; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Apr 2011 Recruitment into the trial is progressing ahead of schedule according to a Geron Corporation media release.
    • 10 Mar 2011 Additional lead trial investigator (Kathy Miller, MD) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top